ModernMedicine Resource Center More Topics

generics

Many Health-Care Groups Laud Generics BillNearly 20 health-care organizations and PBMs come out in favor of FAST Generics Act.
CVS Generic Drugs Suit Fails to Get Class ActionCalifornia judge blocks 11 classes in suit that claims CVS charged insurers and insured patients more than uninsured patients.
FDA Approves 800 Generics in 2016, but Legislators Think Process Should Be FasterFDA set a record for generics approval, but is the process still too cumbersome?
$96.5 Million Generic Payout Latest Trouble for MylanA $96.5 million settlement is the latest in a series of pricing and competition issues Mylan has faced in the past year.
How New Biosimilars Will Impact the MarketMore biosimilars are coming onto the market , including competitors for Remicade and Neulasta.
CVS, Cigna on board with generic EpiPensThe urgent need for a less-expensive epinephrine auto-injector is now being addressed.
Generics and biosimilars, key to Trump drug price concernsIf pharma is “getting away with murder” with drug pricing, more generic and biosimilars can help control costs, says this group.
Issues about biosimilar substitutionAt a time when biosimilars are of strong interest to insurers and health care systems for cost control, physicians are not rushing to issue a blank check for their substitution. Details here.
Pharmacy prices vary widely for generic heart drugsThe prices of heart failure drugs at retail pharmacies vary widely, and uninsured patients may not be able to afford them, researchers have found.
Generic drugs save U.S. $227 billionGeneric drugs produced $227 billion in savings for the U.S. healthcare system in 2015